Flagship Harbor Advisors LLC Sells 301 Shares of GSK plc (NYSE:GSK)

Flagship Harbor Advisors LLC reduced its position in shares of GSK plc (NYSE:GSK) by 2.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 10,611 shares of the pharmaceutical company’s stock after selling 301 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in GSK were worth $359,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in GSK. FMR LLC lifted its position in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in GSK in the 2nd quarter valued at $52,487,000. Fisher Asset Management LLC lifted its holdings in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares during the period. Finally, Bridgewater Associates LP increased its holdings in shares of GSK by 107.3% in the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after purchasing an additional 500,010 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

GSK has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Down 1.1 %

Shares of GSK stock opened at $35.12 on Wednesday. The stock has a market cap of $72.78 billion, a P/E ratio of 22.80, a price-to-earnings-growth ratio of 1.31 and a beta of 0.63. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a 50 day simple moving average of $33.94 and a 200 day simple moving average of $37.78.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.